{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:05:58Z","timestamp":1771293958702,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"BIAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s43440-022-00411-x","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T17:02:36Z","timestamp":1663002156000},"page":"956-968","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Voltage-clamp evidence of GABAA receptor subunit-specific effects: pharmacodynamic fingerprint of chlornordiazepam, the major active metabolite of mexazolam, as compared to alprazolam, bromazepam, and zolpidem"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-932X","authenticated-orcid":false,"given":"H\u00e9lder","family":"Fernandes","sequence":"first","affiliation":[]},{"given":"V\u00e2nia","family":"Batalha","sequence":"additional","affiliation":[]},{"given":"Ellen","family":"Braksator","sequence":"additional","affiliation":[]},{"given":"Simon","family":"Hebeisen","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Bonif\u00e1cio","sequence":"additional","affiliation":[]},{"given":"Maria Augusta","family":"Vieira-Coelho","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"issue":"3","key":"411_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1124\/pr.108.00505","volume":"60","author":"R Olsen","year":"2008","unstructured":"Olsen R, Sieghart W. International union of pharmacology. LXX. Subtypes of \u03b3-aminobutyric AcidA receptores: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev. 2008;60(3):243\u201359.","journal-title":"Pharmacol Rev"},{"key":"411_CR2","first-page":"388","volume-title":"Stahl's essential psychopharmacology: neuroscientific basis and practical applications","author":"SM Stahl","year":"2013","unstructured":"Stahl SM. Anxiety disorders and anxiolytics (chapter 9). In: Stahl\u2019s essential psychopharmacology: neuroscientific basis and practical applications. forth. New York: Cambridge University Press; 2013. p. 388\u2013419.","edition":"forth"},{"issue":"2","key":"411_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0924-977X(95)00072-W","volume":"6","author":"D Graham","year":"1996","unstructured":"Graham D, Faure G, Besnard F, Langer SZ. Pharmacological profile of benzodiazepine site ligands wit recombinant GABAA receptor subtypes. Eur Neuropsychopharmacol. 1996;6(2):119\u201325.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl5","key":"411_CR4","first-page":"6","volume":"68","author":"NL Harrison","year":"2007","unstructured":"Harrison NL. Mechanisms of sleep induction by GABA(A) receptor agonists. J Clin Psychiatry. 2007;68(Suppl5):6\u201312.","journal-title":"J Clin Psychiatry"},{"key":"411_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2147\/NDT.S164307","volume":"14","author":"T Cheng","year":"2018","unstructured":"Cheng T, Wallace DM, Ponteri B, Tuli M. Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects. Neuropsychiatry Dis Treat. 2018;14:1351\u201361.","journal-title":"Neuropsychiatry Dis Treat"},{"issue":"4","key":"411_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","volume":"34","author":"KR Tan","year":"2011","unstructured":"Tan KR, Rudolph U, L\u00fcscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011;34(4):188\u201397.","journal-title":"Trends Neurosci"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/cercor\/bhm160","volume":"18","author":"AB Ali","year":"2008","unstructured":"Ali AB, Thomson AM. Synaptic a5 subunit-containing GABAA receptors mediate IPSPs elicited by dendrite-preferring cells in rat neocortex. Cereb Cortex. 2008;18:1260\u201371.","journal-title":"Cereb Cortex"},{"issue":"5","key":"411_CR8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1523\/JNEUROSCI.0567-18.2018","volume":"39","author":"E Magnin","year":"2019","unstructured":"Magnin E, Francavilla R, Amalyan S, Gervais E, David LS, Luo X, et al. Input-specific synaptic location and function of the \u03b15 GABAA receptor subunit in the mouse CA1 hippocampal neurons. J neurosci. 2019;39(5):788\u2013801.","journal-title":"J neurosci"},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-pharmtox-011613-135947","volume":"54","author":"U Rudolph","year":"2014","unstructured":"Rudolph U, M\u00f6hler H. GABAA Receptor Subtypes. Therapeutic potential in down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol. 2014;54:483\u2013507.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"411_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1359-6446(03)02703-X","volume":"8","author":"PJ Whiting","year":"2003","unstructured":"Whiting PJ. GABAA Receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. 2003;8(10):445\u201350.","journal-title":"Drug Discov Today"},{"key":"411_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.2174\/156802611795371350","volume":"11","author":"JR Atack","year":"2011","unstructured":"Atack JR. GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics. Curr top Med Chem. 2011;11:1176\u2013202.","journal-title":"Curr top Med Chem"},{"key":"411_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41401-018-0185-5","volume":"40","author":"X Chen","year":"2019","unstructured":"Chen X, Gerven JV, Cohen A, Jacobs G. Human pharmacology of positive GABAA subtype-selective receptor modulators for the treatment of anxiety. Acta Pharmacol Sin. 2019;40:571\u201382.","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"411_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrd3502","volume":"10","author":"U Rudolph","year":"2012","unstructured":"Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2012;10(9):685\u201397.","journal-title":"Nat Rev Drug Discov"},{"key":"411_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","volume":"33","author":"P Skolnick","year":"2012","unstructured":"Skolnick P. Anxioselective anxiolytics: on a quest for the Holy Grail. Trends Pharmacol Sci. 2012;33:611\u201320.","journal-title":"Trends Pharmacol Sci"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"108035","DOI":"10.1016\/j.pharmthera.2021.108035","volume":"234","author":"R Cerne","year":"2022","unstructured":"Cerne R, Lippa A, Poe M, Smith J, Jin X, Ping X, et al. GABAkines - advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors. Pharmacol Ther. 2022;234:108035.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"411_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-014-0016-7","volume":"3","author":"H Fernandes","year":"2014","unstructured":"Fernandes H, Moreira R. Mexazolam: clinical efficacy and tolerability. Neurol Ther. 2014;3(1):1\u201314.","journal-title":"Neurol Ther"},{"issue":"3","key":"411_CR17","first-page":"125","volume":"14","author":"MAV Coelho","year":"1997","unstructured":"Coelho MAV, Garrett J. Mexazolam in anxiety disorders: results of a multicenter trial. Adv Ther. 1997;14(3):125\u201333.","journal-title":"Adv Ther"},{"issue":"4","key":"411_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00044011-200323040-00003","volume":"23","author":"L Ferreira","year":"2003","unstructured":"Ferreira L, Figueira ML, Bessa-Peixoto A, Marieiro A, Albuquerque R, Paz C, et al. Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder. Clin Drug Invest. 2003;23(4):235\u201343.","journal-title":"Clin Drug Invest"},{"issue":"10","key":"411_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/00044011-200222100-00004","volume":"22","author":"P Silveira","year":"2002","unstructured":"Silveira P, Vaz-da-Silva M, Dolgner A, Almeida L. Psychomotor effects of mexazolam vs. placebo in healthy volunteers. Clin Drug Invest. 2002;22(10):677\u201384.","journal-title":"Clin Drug Invest"},{"issue":"3","key":"411_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000118609","volume":"22","author":"M Bourin","year":"1989","unstructured":"Bourin M, Auget JL, Colombel MC, Larousse C. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology. 1989;22(3):141\u20135.","journal-title":"Neuropsychobiology"},{"issue":"4","key":"411_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00213-006-0669-8","volume":"191","author":"TR Leufkens","year":"2007","unstructured":"Leufkens TR, Vermeeren A, Smink BE, van Ruitenbeek P, Ramaekers JG. Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg. Psychopharmacology. 2007;191(4):951\u20139.","journal-title":"Psychopharmacology"},{"issue":"1","key":"411_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-2007-1014573","volume":"22","author":"K Schaffler","year":"1989","unstructured":"Schaffler K, Klausnitzer W. Placebo-controlled study on acute and subchronic effects of buspirone vs bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers. Pharmacopsychiatry. 1989;22(1):26\u201333.","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"411_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0893-133X(02)00310-X","volume":"27","author":"JC Verster","year":"2002","unstructured":"Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study. Neuropsychopharmacology. 2002;27(2):260\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"411_CR24","first-page":"89","volume":"13","author":"R Ropert","year":"1987","unstructured":"Ropert R, Bernes J, Dachary JM. Efficacy and tolerance of alprazolam and bromazepam in flexible doses. Double-blind study in 119 ambulatory anxious patients. Encephale. 1987;13(2):89\u201395.","journal-title":"Encephale"},{"issue":"23","key":"411_CR25","first-page":"1392","volume":"148","author":"LM Sonne","year":"1986","unstructured":"Sonne LM, Bruun-Hansen J. Alprazolam (Tafil) and bromazepam (Lexotan) in the treatment of anxiety. A randomized, double-blind comparison in psychiatric outpatients. Ugeskr Laeger. 1986;148(23):1392\u20135.","journal-title":"Ugeskr Laeger"},{"issue":"2","key":"411_CR26","first-page":"77","volume":"14","author":"A Vaz Serra","year":"1993","unstructured":"Vaz Serra A, Firmino H. Estudo cl\u00ednico com dupla oculta\u00e7\u00e3o comparando mexazolam com bromazepam. Psiquiatr Cl\u00edn. 1993;14(2):77\u201384.","journal-title":"Psiquiatr Cl\u00edn"},{"issue":"4","key":"411_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00044011-200121040-00003","volume":"21","author":"A Vaz Serra","year":"2001","unstructured":"Vaz Serra A, Figueira ML, Bessa-Peixoto A, Firmino H, Albuquerque R, Paz C, et al. Mexazolam and alprazolam in the treatment of generalised anxiety disorders, a double-blind, randomised clinical trial. Clin Drug Invest. 2001;21(4):257\u201363.","journal-title":"Clin Drug Invest"},{"key":"411_CR28","unstructured":"Miyakoshi N, Shindo H. Whole-body Autoradiography of RAZ-386-14C after Oral Administration to Mice. RCR. 1971;115\u2013042."},{"issue":"4","key":"411_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3109\/00498258409151418","volume":"14","author":"JG Allen","year":"1984","unstructured":"Allen JG, Galloway DB, Ehsanullah RS, Ruane RJ, Bird HA. The effect of bromazepam (Lexotan) administration on antipyrine pharmacokinetics in humans. Xenobiotica. 1984;14(4):321\u20136.","journal-title":"Xenobiotica"},{"issue":"1","key":"411_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","volume":"12","author":"N Ait-Daoud","year":"2018","unstructured":"Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 2018;12(1):4\u201310.","journal-title":"J Addict Med"},{"issue":"2","key":"411_CR31","first-page":"214","volume":"13","author":"C Griffin","year":"2013","unstructured":"Griffin C, Kaye AM, Kaye AD. Benzodiazepine pharmacology and central nervous system \u2013 mediated effects. Ochsner J. 2013;13(2):214\u201323.","journal-title":"Ochsner J"},{"issue":"6","key":"411_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00003088-199324060-00003","volume":"24","author":"DJ Greenblatt","year":"1993","unstructured":"Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet. 1993;24(6):453\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"7740","key":"411_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0832-5","volume":"565","author":"S Masiulis","year":"2019","unstructured":"Masiulis S, Desai R, Uchanski T, Martin IS, Laverty D, Karia D, et al. GABAA Receptor signalling mechanisms revealed by structural pharmacology. Nature. 2019;565(7740):454\u20139.","journal-title":"Nature"},{"issue":"6","key":"411_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00003088-199324060-00003","volume":"24","author":"DJ Greenblatt","year":"1993","unstructured":"Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam. Clin Pharmacokinet. 1993;24(6):453\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"411_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1517\/17425255.2013.759209","volume":"9","author":"AC Altamura","year":"2013","unstructured":"Altamura AC, Moliterno D, Paletta S, Maffini M, Maui MC, Bareggi S. Understanding the pharmacolinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013;9(4):423\u201340.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"411_CR36","unstructured":"Yamaguchi K et al. Determination of blood and urinary concentration after CS-386 administration in Human (Report no.1). Anal Metab Res Cent Res Lab. 1997;124\u2013282."},{"issue":"3","key":"411_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","volume":"29","author":"P Salva","year":"1995","unstructured":"Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995;29(3):142\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"411_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00426594","volume":"52","author":"T Kamioka","year":"1977","unstructured":"Kamioka T, Nakayama I, Akiyama S, Takagi H. Effects of oxazolam, cloxazolam, and CS-386, new anti-anxiety drugs, on socially induced suppression and aggression in pairs of monkeys. Psychopharmacology. 1977;52:17\u201323.","journal-title":"Psychopharmacology"},{"key":"411_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1476-5381.2011.01763.x","volume":"166","author":"S Masneuf","year":"2012","unstructured":"Masneuf S, Buetler J, Koester C, Crestani F. Role of a1- and a2-GABAA receptors in mediating the respiratory changes associated with benzodiazepine sedation. Br J Pharmacol. 2012;166:339\u201348.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"411_CR40","first-page":"88","volume":"49","author":"E Sana","year":"1999","unstructured":"Sana E, Davide P, Tuveri F, Massa F, Maciocco E, Acquas C, Floris C, et al. Molecular and neurochemical evaluation of the effects of etiozolam on GABAA receptors under normal and stress conditions. Arzneim-Forsch\/Drug Res. 1999;49(1):88\u201395.","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"411_CR41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.phrs.2019.04.034","volume":"145","author":"C Mattei","year":"2019","unstructured":"Mattei C, Taly A, Soualah Z, Saulais O, Henrion D, Gu\u00e9rineau NC, et al. Involvement of the GABAA receptor \u03b1 subunit in the mode of action of etifoxine. Pharmacol Res. 2019;145:1042\u201350.","journal-title":"Pharmacol Res"},{"issue":"46","key":"411_CR42","doi-asserted-by":"publisher","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","volume":"25","author":"R Dias","year":"2005","unstructured":"Dias R, Sheppard W, Fradley RL, Garrett E, Stanley J, Tye S, et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci. 2005;25(46):10682\u20138.","journal-title":"J Neurosci"},{"issue":"2A","key":"411_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1590\/S0004-282X2005000200008","volume":"63","author":"F Puga","year":"2005","unstructured":"Puga F, Veiga H, Cagy M, McDowell K, Piedade R, Ribeiro P. Analysis of the influence of bromazepam on cognitive performance through the visual evoked potential (P300). Arq Neuropsiquiatr. 2005;63(2A):228\u201334.","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"411_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00213-005-0172-7","volume":"183","author":"I Hindmarch","year":"2005","unstructured":"Hindmarch I, Trick L, Ridout F. A Double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology. 2005;183(2):133\u201343.","journal-title":"Psychopharmacology"},{"issue":"19","key":"411_CR45","doi-asserted-by":"publisher","first-page":"7220","DOI":"10.1523\/JNEUROSCI.17-19-07220.1997","volume":"17","author":"M Galarreta","year":"1997","unstructured":"Galarreta M, Hestrin S. Properties of GABAA receptores underlying inhibitory synaptic currents in neocortical pyramidal neurons. J Neurosci. 1997;17(19):7220\u20137.","journal-title":"J Neurosci"},{"key":"411_CR46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0166-2236(96)80037-3","volume":"19","author":"MV Jones","year":"1996","unstructured":"Jones MV, Westbrook GL. The impact of receptor desensitization on fast synaptic transmission. Trends Neurosci. 1996;19:96\u2013101.","journal-title":"Trends Neurosci"},{"issue":"21","key":"411_CR47","doi-asserted-by":"publisher","first-page":"7914","DOI":"10.1523\/JNEUROSCI.20-21-07914.2000","volume":"20","author":"LS Overstreet","year":"2000","unstructured":"Overstreet LS, Jones MV, Westbrook GL. Slow Desensitization regulates the availability of synaptic GABAA receptors. J Neurosci. 2000;20(21):7914\u201321.","journal-title":"J Neurosci"},{"issue":"17","key":"411_CR48","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1523\/JNEUROSCI.6495-11.2012","volume":"32","author":"MD Eyre","year":"2012","unstructured":"Eyre MD, Renzi M, Farrant M, Nusser Z. Setting the time course of inhibitory synaptic currents by mixing multiple GABAA receptor \u03b1 subunit isoforms. J Neurosci. 2012;32(17):5853\u201367.","journal-title":"J Neurosci"},{"key":"411_CR49","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0896-6273(00)80382-7","volume":"19","author":"Z Nusser","year":"1997","unstructured":"Nusser Z, Cull-Candy S, Farrant M. Differences in synaptic GABAA receptor number underlie variation in GABA mini amplitude. Neuron. 1997;19:697\u2013709.","journal-title":"Neuron"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-022-00411-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T20:25:26Z","timestamp":1666383926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-022-00411-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1007\/s43440-022-00411-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H\u00e9lder Fernandes, V\u00e2nia Batalha, Maria Jo\u00e3o Bonif\u00e1cio and Patr\u00edcio Soares-da-Silva were employees of BIAL\u2014Portela & C\u00aa S.A at the time of the study. Simon Hebeisen and Ellen Braksator were employees of B'SYS GmbH at the time of the study. B'SYS GmbH received a grant from BIAL\u2014Portela & C\u00aa, S.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}